期刊文献+

丙泊酚对围术期应激反应的影响 被引量:9

下载PDF
导出
摘要 机体在各种应激刺激的作用下,会出现以交感神经系统和下丘脑_垂体_肾上腺皮质轴兴奋为主的一系列变化,引发应激反应。适当的应激反应能够提高机体对应激时伤害性刺激的耐受程度,而强烈的应激将影响机体的免疫系统,对机体产生不良影响。本文就围术期应激反应和丙泊酚对应激反应的影响作一综述。
出处 《汕头大学医学院学报》 2005年第2期126-128,共3页 Journal of Shantou University Medical College
  • 相关文献

参考文献22

  • 1Brechard S,Bueb JL,Tschirhart EJ.Interleukin-8 primes oxidative burst in neutrophil-like HL-60 through changes in cytosolic calcium[J].Cell Calcium,2005,37(6):531-540.
  • 2Hirota K,Sato Y,Hashimoto Y,et al.Relaxant effect of propofol on the airway dogs[J].Br J Anaesth,1999,83(11):292-295.
  • 3Galley HF,Dubbels AM,Webster NR. The effect of midazolam and propofol on interleukin-8 from human polymorphonuclear leukocytes[J].Anesth Analg,1998,86(11):289-293.
  • 4Rossano F,Tufano R,Cipollaro De L,et al.Anesthetic agents induce human mononuclear leukocytes to release cytokines[J].Immunopharmacol Immunotoxicol,1992,14(5):439-450.
  • 5Inada T,Yamanouchi Y,Jomura S,et al.Effect of propofol and isoflurane anaesthesia on the immune response to surgery[J].Anaesthesia,2004,59(10):954-959.
  • 6Taniguchi T,Yamamoto K,Ohmoto N,et al.Effects of propofol on hemodynamic and inflammatory response to endotoxemia in rats[J].Crit Care Med,2000,28(2):1 101-1 106.
  • 7Kadkhodaee M,Qasemi A. Inhibition of inducible nitric oxide synthase reduces lipopolysaccharide induced renal injury in the rat[J].Clin Exp Pharmacol Physiol,2004,31(12):842-846.
  • 8Yabe Y,Nishikawa M,Tamada A,et al.Targetted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives[J].J Pharmacol Exp Ther,1999,289(8):1 176-1 184.
  • 9Todorovic SM,Perez RE,Lingle CJ.Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants[J].Mol Pharmacol,2000,58(12):98-108.
  • 10Daskalopoulos R,Korcok J,Farhangkhgoee P,et al.Propofol protection of sodium-hydrogen exchange activity sustains glutamate uptake during oxidative stress[J].Anesth Analg,2001,93(10):1 199-1 204.

二级参考文献15

  • 1Park JB, Schifffin EL. ET (A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats[J] I. Hypertention,2001,37(6) :1444-1449.
  • 2Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hyoxia-induced hypertension [ J ]. Hypertension, 2001,37 ( 2 part2) :511-515.
  • 3Willette RN,Anderson KM, Nelson AH, et al. Enrasentan improves survival,limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction[J]. J Cardiovasc Pharmacol,2001,38(4) :606-617.
  • 4Krum H,Viskoper RJ,Lacourciere Y, et al. Bosentan Hypertension investigators. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension [ J ]. N Engl J Med,1998 ,338 :784-790.
  • 5MacCarthy PA ,Grocott-Mason R ,Prendergast BD, et al. Contrasting inotropic effects of endogenous endothelin in the normol and fail human heat. Studies with an intracoronary ETA receptor antagonists[ J ]. Circulation ,2000,101:142-147.
  • 6Picard P, Smith PJW, Monge JC, et al. Coordinated up-regulation of the cardiac endothelin system in a rat modil of heart failure [ J ]. J Cardiovasc Pharmacol, 1998,31 ( Suppl 1 ) : S294-S297.
  • 7Schalcher C,Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemedynamic parameters in patients with advanced heart failure [ J ]. Am Heart J, 2001,142(2) :340-9.
  • 8Torre AG,Young JB,Durand J, et al. Hemodynamic effect of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with clss Ⅲ to Ⅳ congestive heart failure [ J ]. Circulation, 2001,103(7) :973-80.
  • 9Miki S,Takeda K, Kiyama M, et al. Modulation of endothelin-1 coronary vasoconstriction in spontaneously hypertensive rots by the nitric oxide system[J]. Am J Hypertens,2000,13:83-87.
  • 10Alberola AM, Revert F, Moya A, et al. Intravenous BQ-123 and Phosphoramidon reduce ventricular ectopic beats and myocardial infart size in dogs submitted to coronary occlusion and reperfusion[ J ]. Gen Pharmaco1,2000,35 ( 3 ) : 143-147.

共引文献12

同被引文献55

引证文献9

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部